Methods and medical uses relating to the treatment of hypoglycaemia

Sabrina Lyngbye Wendt; Ajenthen Ranjan; Henrik Madsen; Kirsten Nørgaard; John Bagterp Jørgensen

Methods and medical uses relating to the treatment of hypoglycaemia

Sabrina Lyngbye Wendt (Inventor), Ajenthen Ranjan (Inventor), Henrik Madsen (Inventor), Kirsten Nørgaard (Inventor), John Bagterp Jørgensen (Inventor)

Research output: Patent

16 Downloads (Pure)

Abstract

Methods and medical uses for determining a dose for a glucagon bolus for administration to patients with diabetes for treating mild or moderate hypoglycaemia, while reducing the risk of, or avoiding, rebound hyperglycaemia are described. This work is based on simulations using pharmacokinetic (PK) and pharmacodynamic (PD) models for glucose, insulin and glucagon to develop an optimum glucagon dosing regimen for treatment of mild or moderate hypoglycaemia depending on ambient insulin levels, while reducing the risk of, or avoiding, rebound hyperglycaemia, for example as may occur when an overly large dose of glucagon is administered to a patient having a hypoglycaemic episode.

Original language	English
IPC	G16H 20/ 17 A I
Patent number	WO2019008033
Filing date	05/07/2017
Country/Territory	International Bureau of the World Intellectual Property Organization (WIPO)
Priority date	05/07/2017
Priority number	GB20170010822
Publication status	Published - 10 Jan 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

FulltextFinal published version, 5.68 MB

OpenUrl availability

Full text

Cite this

@misc{0e87e6188c8549e29fe437849749dade,

title = "Methods and medical uses relating to the treatment of hypoglycaemia",

abstract = "Methods and medical uses for determining a dose for a glucagon bolus for administration to patients with diabetes for treating mild or moderate hypoglycaemia, while reducing the risk of, or avoiding, rebound hyperglycaemia are described. This work is based on simulations using pharmacokinetic (PK) and pharmacodynamic (PD) models for glucose, insulin and glucagon to develop an optimum glucagon dosing regimen for treatment of mild or moderate hypoglycaemia depending on ambient insulin levels, while reducing the risk of, or avoiding, rebound hyperglycaemia, for example as may occur when an overly large dose of glucagon is administered to a patient having a hypoglycaemic episode.",

author = "{Lyngbye Wendt}, Sabrina and Ajenthen Ranjan and Henrik Madsen and Kirsten N{\o}rgaard and {Bagterp J{\o}rgensen}, John",

year = "2019",

month = jan,

day = "10",

language = "English",

type = "Patent",

note = "WO2019008033; G16H 20/ 17 A I",

}

TY - PAT

T1 - Methods and medical uses relating to the treatment of hypoglycaemia

AU - Lyngbye Wendt, Sabrina

AU - Ranjan, Ajenthen

AU - Madsen, Henrik

AU - Nørgaard, Kirsten

AU - Bagterp Jørgensen, John

PY - 2019/1/10

Y1 - 2019/1/10

N2 - Methods and medical uses for determining a dose for a glucagon bolus for administration to patients with diabetes for treating mild or moderate hypoglycaemia, while reducing the risk of, or avoiding, rebound hyperglycaemia are described. This work is based on simulations using pharmacokinetic (PK) and pharmacodynamic (PD) models for glucose, insulin and glucagon to develop an optimum glucagon dosing regimen for treatment of mild or moderate hypoglycaemia depending on ambient insulin levels, while reducing the risk of, or avoiding, rebound hyperglycaemia, for example as may occur when an overly large dose of glucagon is administered to a patient having a hypoglycaemic episode.

AB - Methods and medical uses for determining a dose for a glucagon bolus for administration to patients with diabetes for treating mild or moderate hypoglycaemia, while reducing the risk of, or avoiding, rebound hyperglycaemia are described. This work is based on simulations using pharmacokinetic (PK) and pharmacodynamic (PD) models for glucose, insulin and glucagon to develop an optimum glucagon dosing regimen for treatment of mild or moderate hypoglycaemia depending on ambient insulin levels, while reducing the risk of, or avoiding, rebound hyperglycaemia, for example as may occur when an overly large dose of glucagon is administered to a patient having a hypoglycaemic episode.

M3 - Patent

M1 - WO2019008033

Y2 - 2017/07/05

ER -

Methods and medical uses relating to the treatment of hypoglycaemia

Abstract

UN SDGs

Access to Document

OpenUrl availability

Fingerprint

Cite this